ESG
Governance
ESG
HL Genomics drives sustainable growth by integrating environmental stewardship,
social responsibility, and robust governance into its operations.
01
Shareholder Structure
Issued Shares / Major Shareholders / General Meeting of Shareholders
02
Board of Directors
Board meetings are held as regular and extraordinary meetings. While they are generally convened by the Chairman, any director may convene a meeting with the Chairman’s consent as necessary for business operations.s.
03
Audit Committee
Board meetings are held as regular and extraordinary meetings. While they are generally convened by the Chairman, any director may convene a meeting with the Chairman’s consent as necessary for business operations.
04
Internal Transaction Committee
The committee was established to enhance management transparency and prevent unfair related-party transactions. It reviews and approves large-scale transactions with related parties in accordance with the Monopoly Regulation and Fair Trade Act.
Issued Shares
(2024.12.31)
| Category | Shares Held (No.) | Ownership (%) |
|---|---|---|
| Domestic | 6,000,000 | 100% |
| Foreign | - | - |
| Total Issued Shares | 6,000,000 | 100% |
← Swipe left or right to see more →
Major Shareholders
(2024.12.31)
| Category | Shares Held (No.) | Ownership (%) |
|---|---|---|
| Hanlim Pharm | 6,000,000 | 100% |
| Treasury Shares | ||
| Others | ||
| Total Issued Shares | 6,000,000 | 100% |
← Swipe left or right to see more →
EGM Voting Results by Agenda
(2025.08.27)
| Proposal | Resolution Type | Subject of Resolution | Outcome | Total Issued Voting Shares |
Total Votes Cast | Votes For / Against & Abstain |
|---|---|---|---|---|---|---|
| Proposal No. 1 | Special | Amendment to the Articles of Incorporation | Approved | 6,000,000 | 6,000,000 |
6,000,000
100%
0
0
|
| Proposal No. 2 | Special | Stock Split | Approved | 6,000,000 | 6,000,000 |
6,000,000
100%
0
0
|
| Proposal No. 3 | Ordinary | Election of Inside Directors (Moon-cheon Ha and 2 others) |
Approved | 6,000,000 | 6,000,000 |
6,000,000
100%
0
0
|
| Proposal No. 4 | Ordinary | Election of Outside Directors (Ji-sun Kim and 1 other) |
Approved | 6,000,000 | 6,000,000 |
6,000,000
100%
0
0
|
| Proposal No. 5 | Ordinary | Election of Audit Committee Member (Ho-seok Shin) |
Approved | 6,000,000 | 6,000,000 |
6,000,000
100%
0
0
|
| Proposal No. 6 | Ordinary | Election of Audit Committee Member (who is an Outside Director) (Ji-sun Kim and 1 other) |
Approved | 6,000,000 | 6,000,000 |
6,000,000
100%
0
0
|
| Proposal No. 7 | Ordinary | Enactment of Internal Transaction Committee Operational Regulations | Approved | 6,000,000 | 6,000,000 |
6,000,000
100%
0
0
|
← Swipe left or right to see more →
Board Composition
As of August 2025, the Board of Directors of HL Genomics consists of seven members (four Inside Directors and three Outside Directors).
(2025.08.27)
| Name | Appointment Date | Term | Classification | Remarks |
|---|---|---|---|---|
| Ho-jin Kim | 2023.07.01 | 3 Years | CEO & Representative Director | Chairman of the Board |
| Moon-cheon Ha | 2025.08.27 | 3 Years | Inside Director | - |
| Geun-hyeok Lee | 2025.08.27 | 3 Years | Inside Director | - |
| Jong-su Park | 2025.08.27 | 3 Years | Inside Director | - |
| Ji-sun Kim | 2025.08.27 | 3 Years | Outside Director | - |
| Young-jin Cheon | 2025.08.27 | 3 Years | Outside Director | - |
| Ho-seok Shin | 2025.08.27 | 3 Years | Outside Director | - |
← Swipe left or right to see more →
Audit Committee Composition
As of late August 2025, the Audit Committee consists of three members, all of whom are Outside Directors responsible for overseeing the company's auditing functions.
(2025.08.27)
| Name | Appointment Date | Term | Classification | Remarks |
|---|---|---|---|---|
| Ho-seok Shin | 2025.08.27 | 3 Years | Outside Director | Chairperson |
| Ji-sun Kim | 2025.08.27 | 3 Years | Outside Director | - |
| Young-jin Cheon | 2025.08.27 | 3 Years | Outside Director | - |
← Swipe left or right to see more →
Internal Transaction Committee Composition
As of late August 2025, the Internal Transaction Committee consists of four members, including three Outside Directors and one Inside Director, responsible for overseeing transactions with related parties. The committee was established to enhance management transparency and prevent unfair inter-company support by reviewing and approving large-scale internal transactions with related parties, as defined by the Monopoly Regulation and Fair Trade Act.
(2025.08.27)
| Name | Appointment Date | Term | Classification | Remarks |
|---|---|---|---|---|
| Ji-sun Kim | 2025.08.27 | 3 Years | Outside Director | Chairperson |
| Ho-seok Shin | 2025.08.27 | 3 Years | Outside Director | - |
| Young-jin Cheon | 2025.08.27 | 3 Years | Outside Director | - |
| Jong-su Park | 2025.08.27 | 3 Years | Inside Director | - |
← Swipe left or right to see more →